AIXC — Aixcrypto Holdings Share News
0.000.00%
Last trade - 00:00Brief: Qualigen Therapeutics, Inc. Reports Financial Results And Corporate Update For Quarter Ending March 31, 2023
Brief: Qualigen Therapeutics Inc Gets Nasdaq Notified For Regained Compliance
Brief: Qualigen Therapeutics, Inc. Reports Q4 Financial Results
Brief: Qualigen Therapeutics Inc Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
Qualigen Therapeutics Inc expected to post a loss of $1.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-CVRx, Tesla, So-Young International
U.S. STOCKS ON THE MOVE-Knight-Swift, BioNTech, US regional banks
Qualigen Therapeutics rises on U.S. patent for cancer drug
Qualigen jumps on U.S. patent for cancer drug
Brief: Composition Of Matter Patent For Qn-302 Granted By United States Patent And Trademark Office
Brief: Data On Potential Biomarker For Qualigen Therapeutics’ Lead Program QN-302 Published In Peer-Reviewed Journal Molecules
Brief: Qualigen Therapeutics Initiates Good Laboratory Practice (Glp) Toxicology Studies On Qn-302
Brief: Qualigen Therapeutics Inc's Board Approves Temporary 20% Reduction To Base Salaries Of All Execs
U.S. STOCKS ON THE MOVE-Oatly, Inari Medical, Netflix
U.S. STOCKS ON THE MOVE-Qualigen Therapeutics, Albertsons, ICON
Qualigen Therapeutics rises on U.S. FDA's 'orphan drug' tag for lead drug
Brief: Qualigen Therapeutics Receives Orphan Drug Designation From The U.S. Food And Drug Administration For Qn-302, A G-Quadruplex (G4) Transcription Inhibitor For The Intended Indication Of Pancreatic Cancer
Brief: Qualigen Therapeutics Updates Developments At Nanosynex Significant Progress
Brief: Qualigen Therapeutics Files For Prospectus By Selling Stockholder Of Up To 5.2 Mln Shares